JITC

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, March 22, 2024
Research, CKPT, FASN, Exercise, Biologics license application, Patent, Safety, Immunotherapy, Patient, FACP, Journal, CRL, Society, Nephrology, JITC, File, Marketing, FDA, Hematology, BLA, Alexion

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.

Key Points: 
  • WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.
  • We look forward to providing additional updates in the second quarter.”
    2023 and Recent Corporate Highlights:
    Checkpoint submitted a BLA to the FDA seeking approval of cosibelimab in January 2023 and the FDA accepted the BLA for filing in March 2023.
  • In December 2023, Checkpoint announced that the U.S. Patent and Trademark Office (“USPTO”) issued a new patent (U.S. Patent No.
  • In July 2023, Checkpoint announced new, longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cSCC.

Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Retrieved on: 
Tuesday, February 13, 2024
OTCQB, Merck, Doctor of Philosophy, TSX, Cancer, Pembrolizumab, MDNA, CPI, Merck & Co., Patient, JITC, Mouse, Pharmaceutical industry

The combination portion of the study is designed to evaluate the potential for a synergistic effect of MDNA11 with KEYTRUDA® in patients with advanced solid tumors.

Key Points: 
  • The combination portion of the study is designed to evaluate the potential for a synergistic effect of MDNA11 with KEYTRUDA® in patients with advanced solid tumors.
  • “Dosing the first patient in the combination arm with MDNA11 and KEYTRUDA® is a significant milestone for Medicenna and are excited with the progress of our novel IL-2 superkine," said Fahar Merchant, PhD, President and CEO of Medicenna.
  • “By combining MDNA11 with KEYTRUDA®, we are building upon the promising data generated to date by MDNA11 as a single agent.
  • MDNA11, with its uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.

Forum Communications International's Flagship Consortium III System Attains Significant Certification from the US Department of Defense

Retrieved on: 
Friday, February 2, 2024
UCCS, Certification, Security, JITC, Conferencing, Government, Risk management, Joint, Confidentiality, Communication, Privacy, RE5, Assessment, Conference, Consortium, Medical device

RICHARDSON, Texas, Feb. 2, 2024 /PRNewswire-PRWeb/ -- The Joint Interoperability Test Command (JITC) issued the following certification:

Key Points: 
  • Being on the DoD Information Network Approved Products list for many years is a testament to our commitment to excellence."
  • Following a meticulous review of the cybersecurity testing results for Forum's Consortium III UCCS Software Release 13.0.0, the RE5 has confirmed that it meets the rigorous requirements for Certification Approval.
  • The approved products list can be viewed at: https://aplits.disa.mil/apl
    Consortium III System and Platform Products Overview:
    The Consortium III UCCS system delivers real-time audio-conferencing capabilities tailored for the Department of Defense.
  • Memorandum for Approved Products Certification Office: Department of Defense Information Network Approved Products List Recommendations for Forum Communications Consortium III Unified Capabilities Conference (UCCS) Software Release 13.0.0 (TN# 2308901/R2-16269-U)

Actelis Announces U.S. Department of Defense JITC Labs Approval for Cybersecurity and Interoperability and Approved Products List Status

Retrieved on: 
Tuesday, January 16, 2024
Voice over IP, IP, Computer security, APL, Government, Joint, Federation, Risk management, HVAC, ASNS, Defense, Interoperability, DISA, Internet of things, JITC, Human voice, Certification, Cryptocurrency

The DoDIN APL, maintained by the Defense Information Systems Agency (DISA) , is the single consolidated list of products that have completed Cybersecurity and Interoperability certification.

Key Points: 
  • The DoDIN APL, maintained by the Defense Information Systems Agency (DISA) , is the single consolidated list of products that have completed Cybersecurity and Interoperability certification.
  • Now, with Actelis products on the APL, the procurement process for JITC certified, cost-effective, and immediately deployable connectivity is now much faster and simpler.
  • “The JITC cybersecurity certification by the Department of Defense demonstrates Actelis’ strength in the area of network security and data protection,” said Barlev.
  • “Security is a core pillar of the Actelis solution, and we are very proud to be certified by the United States military.”

Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab

Retrieved on: 
Tuesday, January 9, 2024
MSD, MDNA, Patient, Neoplasm, PD-1, Mouse, OTCQB, Cancer, TSX, Pembrolizumab, CPI, JITC, Pharmaceutical industry

“We are very pleased to announce initiation of the combination study of MDNA11 and the PD-1 inhibitor, pembrolizumab, the leading checkpoint inhibitor therapy,” said Fahar Merchant, Ph.D., President and CEO of Medicenna.

Key Points: 
  • “We are very pleased to announce initiation of the combination study of MDNA11 and the PD-1 inhibitor, pembrolizumab, the leading checkpoint inhibitor therapy,” said Fahar Merchant, Ph.D., President and CEO of Medicenna.
  • “Having established an appropriate dose for monotherapy as well as demonstrating its early clinical validation we believe MDNA11 may further enhance anti-tumor activity when combined with pembrolizumab in patients that do not respond or develop resistance to checkpoint therapy.
  • We look forward to reporting preliminary results from both the monotherapy expansion and combination escalation arms of the Phase 2 study in the first half of 2024.”
    In the Phase 1 monotherapy dose escalation and dose evaluation portions of the study, MDNA11 was well tolerated with promising single-agent activity.
  • MDNA11, with its uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.

Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, November 13, 2023
Safety, Food, D, BLA, Exercise, JITC, Patient, Journal, Research, U.S. FDA, FDA, Immunotherapy, Oncology, PDUFA, Society, CKPT, Pharmaceutical industry, Cryptocurrency, Cancer, Checkpoint

WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2023, and recent corporate highlights.

Key Points: 
  • Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024
    WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2023, and recent corporate highlights.
  • In July 2023, Checkpoint announced new, longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cSCC.
  • Also in July 2023, Checkpoint completed a registered direct offering priced at-the-market under Nasdaq rules for total gross proceeds of $10 million.
  • Net loss for the third quarter of 2023 included $0.9 million of non-cash stock expenses, compared to $0.8 million for the third quarter of 2022.

Cyberlux Corporation (OTC: CYBL) Releases Third Quarter 2023 Financial and Operational Results; Announces Transformative Actions to Refocus the Company on the Defense Technology Sector

Retrieved on: 
Tuesday, November 21, 2023
Contracts, Defense, Other Defense, Aircraft, Acquisition, Operation Sky Monitor, Defense Logistics Agency, Corporation, ADS, Telecommunications, Growth, Government agency, Government, Safariland, Agreement, SDR, ISR, Partnership, OTC, Aircraft systems, Advanced Intelligent Tape, FBD, USSOCOM, Hardware, JITC, USAI, SAS, UAS, OTC Markets Group, Security, Communication, Publishing, HF, MCT, CYBL, CE, MB, Software, VHF, Human, Dedicated short-range communications, Cryptocurrency, Satellite navigation device, Cassette tape, United States Army, Perception, Reconnaissance

Our operating period ended September 30, 2023, has set the stage for the Company to capitalize on remarkable opportunities across the global Defense Technology markets.

Key Points: 
  • Our operating period ended September 30, 2023, has set the stage for the Company to capitalize on remarkable opportunities across the global Defense Technology markets.
  • Our work to remove the CE designation continues, but the Company is driving breakthrough results regardless of these temporary obstacles.
  • As the Company develops advanced technology products, we will identify core technology and product companies, and these companies will become the Cyberlux growth catalysts.
  • As the results show, Cyberlux is building a global enterprise and developing into a leading technology growth company.

Agile Defense Wins TEC II Single Award IDIQ Contract Supporting DISA

Retrieved on: 
Tuesday, November 21, 2023
Air force, DISA, Joint, DARPA, Navy, Defense Information Systems Agency, JITC, Certification, JSP, IDIQ, The, Joint Interoperability Test Command, Data collection, Army, TEC, Growth, Evaluation, Arms industry, Defense

"Agile Defense's unwavering commitment to the defense mission is driving how we impact the market with our client-focused solutions," Agile Defense CEO Rick Wagner explained.

Key Points: 
  • "Agile Defense's unwavering commitment to the defense mission is driving how we impact the market with our client-focused solutions," Agile Defense CEO Rick Wagner explained.
  • "Being able to compete and win a full-and-open IDIQ contract confirms our strategic investments align with our customer needs."
  • News of the award arrived during an energetic period of rapid growth for Agile Defense, just weeks after welcoming Rick Wagner as the new CEO.
  • Agile Defense's joint venture, Agile-Bot II, was also recently selected to deliver credentialing services to DISA Joint Service Provider (JSP).

Eventide Communications' NexLog DX-FIPS Recorders Achieve JITC Certification

Retrieved on: 
Tuesday, November 14, 2023
DISA, Joint, Defense Information Systems Agency, JITC, Radio, Learning, Multimedia, Security Technical Implementation Guide, Joint Interoperability Test Command, Communication, Eventide, Government, NIST, Certification, Medical device, Defense

"The JITC certification is a testament to our unwavering commitment to delivering secure, reliable, and cutting-edge solutions that meet the highest industry standards," said Brad Basile, COO of Eventide Communications.

Key Points: 
  • "The JITC certification is a testament to our unwavering commitment to delivering secure, reliable, and cutting-edge solutions that meet the highest industry standards," said Brad Basile, COO of Eventide Communications.
  • "Our NexLog DX-FIPS recorders not only meet, but exceed the stringent guidelines set by NIST and the various applicable Security Technical Implementation Guides (STIGs) within."
  • Our JITC-approved recorders are designed with military-grade security and reliability to provide clear, reliable audio capture and advanced data management capabilities.
  • If you are interested in learning more about the advantages of implementing JITC-certified recorders, please visit our JITC landing page or contact our Eventide sales team to request a demo today.

Enterome Presents Immune-Monitoring Data on EO2401 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Wednesday, November 1, 2023
BIRC5, Society for Immunotherapy of Cancer, Nivolumab, Inflammation, Adrenal tumor, Immunotherapy, Journal, IL13RA2, SITC, Service provider, JITC, Abstract, Annual general meeting, FOXM1, Patient, Glioblastoma, Peptide, Vaccine, Cancer

PARIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced the presentation of immune-monitoring data from the ongoing trials of EO2401 in adrenal tumors and recurrent glioblastoma at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place from November 1-5, 2023, in San Diego, California, and virtually.

Key Points: 
  • PARIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced the presentation of immune-monitoring data from the ongoing trials of EO2401 in adrenal tumors and recurrent glioblastoma at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place from November 1-5, 2023, in San Diego, California, and virtually.
  • EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics™ peptide-based immunotherapy.
  • The poster details are as follows:
    Title: “EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1-19/SPENCER Study”
    In addition, research collaborator from Tübingen University, Germany, presents immune response data from the ongoing Phase 1/2 ROSALIE study of EO2401 in combination with nivolumab in recurrent glioblastoma.
  • Title: “Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1-18/ROSALIE study”
    All abstracts will subsequently be published as a supplement in the Journal for ImmunoTherapy of Cancer (JITC), Dec. 2023.